Published in Med Sci (Paris) on February 01, 2005
CNF1 exploits the ubiquitin-proteasome machinery to restrict Rho GTPase activation for bacterial host cell invasion. Cell (2002) 2.77
E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell (2006) 2.50
The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity. J Biol Chem (2003) 2.02
Ubiquitin-independent degradation of proteins by the proteasome. Biochim Biophys Acta (2008) 1.69
Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol Cell Biol (2005) 1.55
SUMO under stress. Biochem Soc Trans (2008) 1.47
SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1. J Cell Biol (2004) 1.24
Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer. Mol Cell Biol (2007) 1.16
Sumoylation inhibits alpha-synuclein aggregation and toxicity. J Cell Biol (2011) 1.13
Transcriptional activation of the adenoviral genome is mediated by capsid protein VI. PLoS Pathog (2012) 1.06
c-Fos proto-oncoprotein is degraded by the proteasome independently of its own ubiquitinylation in vivo. Mol Cell Biol (2003) 1.06
The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression. Oncogene (2003) 1.04
SUMOylation regulates the transcriptional activity of JunB in T lymphocytes. J Immunol (2008) 1.03
Heterodimerization with Jun family members regulates c-Fos nucleocytoplasmic traffic. J Biol Chem (2007) 0.99
Heterodimerization with different Jun proteins controls c-Fos intranuclear dynamics and distribution. J Biol Chem (2010) 0.96
Effects of virion surface gp120 density on infection by HIV-1 and viral production by infected cells. Virology (2005) 0.96
Interaction with 14-3-3 adaptors regulates the sorting of hMex-3B RNA-binding protein to distinct classes of RNA granules. J Biol Chem (2008) 0.94
JunB breakdown in mid-/late G2 is required for down-regulation of cyclin A2 levels and proper mitosis. Mol Cell Biol (2008) 0.93
A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog (2010) 0.92
Ubiquitin-independent- versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: is there a unique answer? Biochimie (2007) 0.91
A novel role for PA28gamma-proteasome in nuclear speckle organization and SR protein trafficking. Mol Biol Cell (2008) 0.91
An NF-kappaB-dependent role for JunB in the induction of proinflammatory cytokines in LPS-activated bone marrow-derived dendritic cells. PLoS One (2010) 0.84
Efficient gene transfer into spleen cells of newborn mice by a replication-competent retroviral vector. Virology (2002) 0.84
High in vivo production of a model monoclonal antibody on adenoviral gene transfer. Hum Gene Ther (2002) 0.84
Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation. Genet Vaccines Ther (2004) 0.82
Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment. J Virol (2005) 0.82
Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies. Blood (2012) 0.82
Monoclonal antibody 667 recognizes the variable region A motif of the ecotropic retrovirus CasBrE envelope glycoprotein and inhibits Env binding to the viral receptor. J Virol (2003) 0.81
Multiple degradation pathways for Fos family proteins. Ann N Y Acad Sci (2002) 0.80
Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice. J Virol (2007) 0.80
Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody. J Virol (2010) 0.80
Fos family protein degradation by the proteasome. Biochem Soc Trans (2008) 0.80
The insertion of an anti-MHC I ScFv into the N-terminus of an ecotropic MLV glycoprotein does not alter its fusiogenic potential on murine cells. Virus Res (2002) 0.79
Mechanisms of delivery of ubiquitylated proteins to the proteasome: new target for anti-cancer therapy? Crit Rev Oncol Hematol (2005) 0.79
The effects of N-terminal insertion into VSV-G of an scFv peptide. Virol J (2006) 0.79
Efficient mother-to-child transfer of antiretroviral immunity in the context of preclinical monoclonal antibody-based immunotherapy. J Virol (2006) 0.79
Skin as a potential organ for ectopic monoclonal antibody production. J Invest Dermatol (2002) 0.78
SUMO2/3 modification of cyclin E contributes to the control of replication origin firing. Nat Commun (2013) 0.78
In vivo infection of mice by replication-competent MLV-based retroviral vectors. Methods Mol Med (2003) 0.78
Monoclonal antibody-based genetic immunotherapy. Curr Gene Ther (2004) 0.77
Chromatin loop organization of the junb locus in mouse dendritic cells. Nucleic Acids Res (2013) 0.76
[Vaccine-like effects of antiviral monoclonal antibodies: a novel therapeutic perspective?]. Med Sci (Paris) (2013) 0.75
Evasion from proteasomal degradation by mutated Fos proteins expressed from FBJ-MSV and FBR-MSV osteosarcomatogenic retroviruses. Biochem Pharmacol (2002) 0.75